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Abstract: Lung cancer is the leading cause of cancer death in the
United States and the world. The high mortality rate results, in part,
from the lack of effective tools for early detection and the inability
to identify subsets of patients who would benefit from adjuvant
chemotherapy or targeted therapies. The development of high-
throughput genome-wide technologies for measuring gene expres-
sion, such as microarrays, have the potential to impact the mortality
rate of lung cancer patients by improving diagnosis, prognosis, and
treatment. This review will highlight recent studies using high-
throughput gene expression technologies that have led to clinically
relevant insights into lung cancer. The hope is that diagnostic and
prognostic biomarkers that have been developed as part of this work
will soon be ready for wide-spread clinical application and will have
a dramatic impact on the evaluation of patients with suspect lung
cancer, leading to effective personalized treatment regimens.
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Lung cancer is the leading cause of cancer death in theUnited States and the world. The high mortality rate
(80–85% within 5 years) results from the lack of effective
screening tools and tools for early-stage diagnosis,1–3 the
inability to identify subsets of patients who would benefit
from adjuvant chemotherapy or adjuvant targeted therapies,
and the slow development of new drug therapies. The devel-
opment of high-throughput genome-wide technologies for
measuring gene expression, such as microarrays, have the
potential to impact the mortality rate of lung cancer patients
by improving diagnosis, prognosis, and treatment.
The use of high-throughput technologies in breast can-
cer illustrates the potential impact that similar approaches
may have in thoracic oncology. Deoxyribonucleic acid
(DNA) microarrays have been used to identify gene expres-
sion signatures comprised of multiple genes that indicate
which estrogen receptor-positive and auxiliary node-negative
patients may benefit from additional chemotherapy. There are
currently three commercially available gene expression based
prognostic tests for breast cancer—Oncotype DX, a 21-gene
assay4 (Genomic Health, Redwood City, CA), MammaPrint,
a 70-gene assay5 (Agendia BV, Amsterdam, the Netherlands),
and H/I, a 2-gene ratio assay6 (AvariaDx, Carlsbad, California).
Currently, there are two ongoing prospective randomized
trials, Trial Assigning Individual Options for Treatment
(TAILORx) to evaluate OncotypeDx, and Microarray in
Node-negative Disease may Avoid ChemoTherapy (MINDACT)
to evaluate MammaPrint versus a prognostic clinical algo-
rithm.7 If these tests prove efficacious, they will be the first of
many prognostic and diagnostic tests based on high-through-
put gene expression measurements. The advantage of multi-
gene biomarkers is that they are able to achieve higher
accuracy than would be possible from a single gene measure
(Figure 1).
This review will highlight recent studies using high-
throughput gene expression technologies that have led to
clinically relevant insights into lung cancer. The studies
present molecular markers for the diagnosis of lung cancer,
the prognosis of early-stage lung cancer, and sensitivity and
response to chemotherapeutic agents (Table 1). Due to the
clinical focus of this review, mechanistic insights into lung
cancer biology and pathogenesis using high-throughput gene
expression technologies (examples include8–10) as well as the
technical, computational, and analytic challenges inherent in
processing and analyzing high-throughput data will not be
discussed. Also, the application of the high-throughput tech-
nologies to study SNPs, DNA methylation, alternative splic-
ing, and protein expression in lung cancer is discussed else-
where.11–14
High-Throughput Technologies
The success of the Human Genome Project coupled with
a variety of technological advances such as rapid oligonucleo-
tide synthesis and microarray chip fabrication has enabled the
development of high-throughput gene expression technologies.
Depending on the experimental design, ribonucleic acid (RNA)
samples are obtained from cell cultures or surgical tissues.
Before RNA isolation and processing, techniques such as laser
capture microdissection15 can be used to obtain a homogeneous
population of cells from tissue specimens.
Microarrays are currently among the most commonly
used technology for quantitatively measuring the expression
of genes or microRNAs in a high throughput manner. Mi-
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croarrays are orderly arrays of spots composed of oligonu-
cleotides complementary to genes/miRNAs that are immobi-
lized onto a solid support such as a glass slide.16,17
Microarrays take advantage of Watson-Crick base pairing,
and therefore, only complementary nucleic acids will hybrid-
ize and produce a signal that can be used as a measure of
expression. The production and use of microarrays requires
several steps including the synthesis of probes, array fabri-
cation, target hybridization, fluorescence scanning, and image
processing to produce a numerical readout of expression.
Complementary DNA microarrays, developed at Stanford
University, use DNA clones (selected from sequence data-
bases) between 500 and 5000 base pairs in length as probes.
Oligonucleotide microarrays, as their name implies, use as
probes short oligonucleotides that have been derived from
gene or miRNA sequences. In addition to microarrays, other
FIGURE 1. Overview of multigene biomarkers. A, While individual genes may show significantly different expression levels
between patients in two disease states (e.g., healthy patients and patients with lung cancer), the distribution of expression
levels for any single gene may overlap sufficiently that no single gene can function as an accurate marker of disease state. The
histograms plot the number of individuals (y axis) with a given expression level of each gene (x axis) as a function of disease
state. For simplicity, this example uses two disease states, but the principle is the same for multiple disease states or a continu-
ous outcome such as survival. B, Hierarchical clustering of gene expression levels across genes that vary between disease states
shows that in aggregate these genes are able to distinguish between the two disease states. The dendrogram at the top of
the panel shows the degree of relatedness between samples. C, A critical step in creating a biomarker from the expression lev-
els of multiple genes is combining the expression levels into a single metric that associates with disease status. In this exam-
ple, we show how following Principal Component Analysis, the values of the first component (x axis) distinguish between the
two disease states. While here we illustrate the use of Principal Component Analysis, there are many methods for performing
this sort of dimensionality reduction. D, The distribution of multigene biomarker scores as a function of disease state shows that
compared with the distribution of expression levels in individual genes, the multigene biomarker can distinguish between the
two disease states with a high degree of accuracy. E, When the expression levels of the genes in the biomarker are measured
in a clinical sample, a prediction can be made as to the disease state of the patient from which the sample was obtained
based on the biomarker score.
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high-throughput sequence-based technologies to measure
gene expression such as serial analysis of gene expression
(SAGE)18 have been used in the past, and technological
advances in sequencing are leading to new massively parallel
sequencing technologies19–21 that will likely be used exten-
sively in future research.
Lung Cancer Diagnosis
The risk for developing lung cancer increases with
cumulative exposure to cigarette smoke. The incidence of
lung cancer, however, even in a high-risk population of
smokers is only approximately 15% over a lifetime.22 Cur-
rently, there are no effective diagnostic biomarkers to identify
which current and former smokers are at the greatest risk for
developing lung cancer. As a result of this failure to detect
high-risk smokers and the low frequency of early stage
detection the 5 year survival rates for lung cancer (approxi-
mately 15%) have not changed appreciably over the past four
to five decades. Previous screening trials with frequent chest
radiographs and sputum cytology have not demonstrated an
effect on lung cancer mortality (reviewed by Jett and
Midthun23). Spiral computerized tomography (CT) scan
screening can detect lung tumors at an earlier stage than
routine chest radiographs. However, while spiral CT can be
highly sensitive it is also nonspecific and many newly de-
tected small lesions have proven on resection to be nonma-
lignant scar tissue or old granulomas rather than early lung
cancers.2 While final results from large-scale randomized
trials using CT scans are still pending, recent work has
suggested that this approach does not improve lung cancer
mortality.24
Developing biomarkers that are highly sensitive, spe-
cific, and identify smokers at high risk for developing lung
cancer or individuals with early stage cancer represents a key
approach to improving lung cancer mortality. To explore the
mechanisms by which individuals respond to the carcino-
genic effects of smoking, several groups have used DNA
microarrays and SAGE to define the genome-wide impact of
smoking and smoking cessation on cytologically normal
bronchial airway epithelial cells25–31 or peripheral blood lym-
phocytes32,33 of never, former, and current smokers.
The results of the above studies suggest that it might be
possible to detect which smokers the carcinogenic effects of
cigarette smoke have resulted in lung cancer. A recent study
by Spira et al.34 used DNA micoarrays to profile the gene
expression patterns of cytologically normal large airway
epithelial cells in current and former smokers undergoing
bronchoscopy for the clinical suspicion of lung cancer. An
80-probeset lung cancer-specific biomarker was developed
based on a training set of samples (n  77) that could
distinguish between smokers with and without lung cancer.
The biomarker was both sensitive and specific when tested on
an independent test set (n  52) and on an additional
prospectively collected set of samples (n 35). This biomar-
ker was also shown to provide information about the likeli-
hood of lung cancer that is independent of clinical risk factors
for lung cancer among patients with nondiagnostic broncho-
scopies.35 By increasing the diagnostic sensitivity of bron-
choscopy, biomarkers such as the one described above, have
the potential to expedite more invasive testing and definitive
therapy for smokers with lung cancer, and reduce invasive
diagnostic procedures for individuals without lung cancer. In
addition, if future studies demonstrate that smoking-induced
cancer-specific alterations in gene expression precede the
development of lung cancer, biomarkers may be useful for
indentifying high-risk lung cancer patients.
Molecular Classification and Characterization
Differences in treatment between non-small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC) make the
distinction between these two types of lung cancer important.
Within NSCLC, there are potential differences in terms of
prognosis and response to newer targeted therapies.36 Accu-
rate molecular classification, therefore, has the potential to
identify different molecular subtypes of NSCLC currently not
recognized by pathologists that would benefit from subtype-
specific therapies. In addition, molecular classification of
tumors may augment surgical-pathologic staging at surgery,
allowing the most appropriate treatment for a given stage of
tumor to be used.
Molecular Classification of Lung Cancer
One of the initial applications of high-throughput gene
expression technology in the area of lung cancer was to
explore whether or not differences in gene expression could
be indentified between the different histologic subtypes of
lung tumors. Two studies in November 2001 began to explore
this question using microarray technology and diverse sets of
lung tumor samples. The broad goals were to identify gene
expression profiles associated with the histologic subtypes of
lung tumors, identify subclasses of adenocarcinoma (AD)
where there is frequent disagreement among pathologists,
associate gene expression profiles with tumor features such as
surgical-pathologic stage as well as survival after resection,
and identify metastases of nonlung origin.
Garber et al.37 profiled the gene expression of 67 lung
tumors with 5 years of clinical follow-up from 56 patients as
well as 5 normal lung samples and 1 fetal lung sample using
24,000 element complementary DNA microarrays. Hierar-
chal clustering of samples according to the expression of the
most variable genes revealed patterns of gene expression that
corresponded to the major morphologic classes of lung tu-
mors: AD (n  41), squamous cell carcinoma (SCC) (n 
16), large cell carcinoma (LCC) (n  5), and SCLC (n  5).
The AD tumors were the most heterogeneous and formed
three distinct clusters. There were differences in survival
between the three groups, and this was in part associated with
tumor grade and lymph node metastases.
In a larger study, Bhattacharjee et al.38 used Affymetrix
U95 microarrays containing 12,600 transcripts to profile gene
expression levels of 17 normal lung samples and 186 lung
tumors that included 127 ADs, 21 SCC, 20 carcinoids, 6
SCLC, and 12 AD tumors suspected to be of nonlung origin.
Using a similar methodology to Garber et al., hierarchal
clustering segregated samples based on histologic subtype
and identified molecular markers associated with each sub-
type. Both studies found, for example, keratin genes were
highly expressed by SCC and genes associated with neuroen-
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docrine differentiation were highly expressed in SCLC. Bhat-
tacharjee et al. examined just the ADs using hierarchal and
probabilistic model-based clustering and identified six dis-
tinct groups. A supervised approach was subsequently used to
identify genes strongly associated with each of the six clus-
ters. One cluster contained normal lung tissue, another cluster
contained tumors suspected to be colon, breast, or liver
metastases, and the remaining four clusters segregated the
ADs based on markers of cell division, proliferation, neu-
roendocrine origin, and type II alveolar pneumocytes. The
clusters were also associated with extent of tumor differen-
tiation, presence of bronchioloalveolar carcinoma (BAC), and
patient outcome even when limited to Stage I tumors.
Both the Garber et al. and Bhattacharjee et al. studies
demonstrated that gene expression patterns could distinguish
between the histologic subtypes of lung cancer and found that
ADs had the greatest heterogeneity. In addition, both studies
demonstrated an association between the AD clusters and
prognosis. The studies, however, lacked independent test sets
to confirm the molecular classifications, however, a study by
Hayes et al.39 demonstrated that the tumor subtypes of AD
were reproducible across the two datasets plus an additional
dataset. The AD specimens also contained a mixture of
subtypes that included BACs with known favorable prog-
noses making it difficult to distinguish between genes related
to prognosis or subtype, and the Bhattacharjee study lacked
clinical data to confirm metastases from extrapulmonary
tumors. Despite these shortcomings, the studies served as a
foundation for future lung cancer gene expression studies.
Several smaller studies followed exploring similar
questions using different analysis techniques, sample sets,
and technologies such as SAGE.40–43 Other studies per-
formed real time polymerase chain reaction (PCR) and im-
munohistochemistry to validate gene expression differences
between lung tumor subtypes,44 distinguish between primary
and metastatic SCC of the lung,45 and explore differences
between lung tumors and lung cancer cell lines.46 In addition,
other studies have identified molecular markers for pulmo-
nary neuroendocrine tumors using DNA microarrays and
linked a subset of these markers to prognosis.47,48 Finally,
these studies identified molecular markers for known histo-
logic subtypes of lung cancer and suggested refinements to
the pathologic classification of tumors. Molecular classifica-
tion of lung tumors may eventually improve prognosis if
newly identified subtypes respond differently to current treat-
ments regimens or if they suggest new subtype-specific drug
targets.
Molecular Staging of Lung Tumors
In addition to molecular classification of tumors, high-
throughput gene expression technologies have been used to
characterize tumor stage. A study by Ramaswamy et al.49
identified a gene expression signature of metastasis that could
distinguish between metastatic and primary ADs from mul-
tiple tumor types. Stage I and II lung ADs from the Bhatta-
charjee et al. dataset separated into two groups with signifi-
cant differences in survival according to the expression of the
metastatic gene signature. When the signature was applied to
other tumor datasets, tumors expressing the metastatic gene
signature consistently had a poor outcome, suggesting that
metastatic potential may be encoded in the primary tumor.
Several studies using the primary lung tumor to predict
lymph node metastases were subsequently published. Kikuchi
et al.50 and Inamura et al51 identified genes associated with
lymph node metastasis among primary lung ADs, and Hoang
et al.52 identified genes associated with nonmetastatic tumors,
those with micrometastases, and those with overt metastasis.
Xi et al.53 used the Bhattacharjee et al. (see above) and the
Beer et al.54 (see Prognosis section below) datasets to exam-
ine whether gene expression in primary AD tumors was
indicative of lymph node metastases. A 318-gene signature
was able to accurately classify node positive patients in the
training (Beer et al.) and test (Bhattacharjee et al.) sets, but
frequently misclassified node negative patients. The classifi-
cation as node negative or positive in the node negative
patients was associated with survival. These studies suggest
that the survival differences observed among Stage I ADs in
the Garber et al. and Bhattacharjee et al. datasets might be
related to the presence of micrometastases or metastatic
potential. The use of gene expression for “molecular staging”
may enhance the sensitivity of clinical and pathologic meth-
ods for staging tumors, improving treatment decisions and
ultimately outcomes for lung cancer patients.
miRNAs Classification of Lung Cancer
miRNAs are short sequences of RNA about 22 nucle-
otides long that regulate gene expression by hybridizing to
complementary sequences of target messenger RNA
(mRNA). The binding of miRNAs to mRNAs can result in
degradation of the mRNA or repression of mRNA translation
into proteins. Recently, expression profiling of miRNAs has
contributed to our knowledge of how these short sequences
are involved in cancer biology. Yanaihara et al.55 focused on
exploring miRNA expression in normal and cancerous lung
tissue. DNA microarrays capable of measuring 352 miRNAs
were used to identify 43 miRNAs that were differentially ex-
pressed between 104 pairs of normal and lung tumor tissue and
6 miRNAs differentially expressed between AD and SCC.
Prognosis
Thirty to 35% of Stage 1 NSCLC patients relapse
following tumor resection.56,57 Clinical trials have indicated a
potential survival advantage for early-stage lung cancer pa-
tients who receive adjuvant chemotherapy.58 However, it
would be useful to identify the subset of these patients who
are at low risk for relapse to spare them the side effects of
unnecessary treatment. Gene expression profiles have the
potential to augment current prognostic indicators such as
clincopathological stage, K-ras and p53 mutations, poor dif-
ferentiation, and high tumor proliferative index.
Prognostic Gene Expression Signatures for
NSCLC
The Garber et al. and Bhattacharjee et al. studies found
correlations between molecular subgroups of lung AD and
prognosis. These findings set the stage for the publication of
several studies that used supervised approaches to identify
genes associated with prognosis among early-stage ADs. The
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supervised approaches first stratify patients by known out-
come, identify genes associated with these outcomes in a set
of training samples, and use these genes and an algorithm to
predict the outcome of additional test set samples. In 2002,
Beer et al.54 used DNA microarrays to measure gene expres-
sion levels in 67 Stage I ADs, 19 Stage III ADs, and 10
non-neoplastic lung tissues. Stage I and III tumors were
divided into training and testing sets and 50 genes associated
with survival were identified across the training set using
univariate Cox proportional-hazard regression modeling. Ex-
pression levels of these genes were combined using a predic-
tion algorithm to calculate a risk index which was then used
to stratify patients into low- and high-risk groups. There was
a significant difference in survival between test set samples as
a whole and the subgroup of Stage I test samples predicted to
be low- or high-risk. Interestingly, stratifying patients by
prognostic markers such as K-ras and p53 mutation status did
not identify subgroups with a significant difference in sur-
vival. After refining the predictor, it was validated across 84
lung AD samples from Bhattacharjee et al. and patients
assigned to the low- and high-risk groups by gene expression
varied significantly in survival. Since the publication of this
study, several other studies have emerged with gene expres-
sion prognostic profiles for early stage NSCLC.59–65
One such study by Potti et al.66 analyzed 89 NSCLC
patients using DNA microarrays to develop a metagene
prediction model capable of predicting disease recurrence.
The model had a higher accuracy than models containing
clinical data alone (age, sex, tumor diameter, stage of disease,
histologic subtype, and smoking history) or both clinical and
gene expression data. The model was 72% accurate across
ACOSOG Z0030 trial samples (n 25), 79% accurate across
CALGB 9761 trial samples (n  84), and 80% accurate
across an independent set of Stage I SCC (n  15). As
proposed by Potti et al., a randomized Phase III trial, CALGB
30506, is about to begin to evaluate the metagene predictor to
direct adjuvant therapy in high risk Stage IA NSCLC pa-
tients. While the prediction model was validated on an inde-
pendent sample set, it remains unclear if the signature is
entirely related to differences in prognosis or recognized
subtypes of AD (patients with BAC were not identified). In
addition, the variables explored in the clinical risk model did
not include potentially important prognostic indicators such
as tumor grade, histologic subtype of AD,67 and the muta-
tional status of cancer-related genes (K-ras, p53). Finally, it is
not clear if there were differences in the use of adjuvant
chemotherapy treatment among the patients that could effect
survival. The trial will hopefully answer several of these
questions that were not addressed in the study.
A study by Lu et al.68 published shortly after the Potti
et al. study, performed a meta-analysis of seven different
datasets,10,38,54,69 including a previously unpublished dataset
of their own, to identify a gene expression signature that
predicts survival in patients with Stage I NSCLC. Genes were
identified that were common to the microarray platforms used
in all of the studies, the datasets were adjusted for systematic
bias, and 197 samples with Stage I NSCLC from 5 of the 7
datasets were used to identify a gene expression signature of
64 genes predictive of survival. The signature had higher
classification power compared with stage, was predictive of
survival among ADs and SCCs, and was able to accurately
predict survival in the two datasets not used to develop the
signature. A subset of the 64 genes was also validated using
quantitative -polymerase chain reaction (RT-PCR) and im-
munohistochemistry. This study demonstrates the feasibility
of combining different Affymetrix DNA microarrays to in-
crease sample size and predictive power and identify a robust
gene expression signature predictive of survival.
Chen et al.70 recently reported a five gene signature
capable of predicting survival among patients with NSCLC.
Sixteen genes were found to be associated with survival
across training and test sets using DNA microarrays measur-
ing 672 previously identified genes71 associated with invasive
activity in invasive NSCLC cell lines. A subset of the sixteen
genes (n 5) were correlated with survival using quantitative
RT-PCR, and this subset was used to create a decision tree
that stratified patients into low- and high-risk for reoccur-
rence. The predictor was tested on an independent set of 60
patients and on the Beer et al.54 dataset. The shortcomings of
this study include a heterogeneous group of samples that
included Stage I, II, and III NSCLC samples and different
subtypes of NSCLC. In addition, Chen et al. chose to focus
on a set of invasive genes derived from NSCLC cell lines
characteristic of the lung tumor, but not the adjacent stromal
tissue. The samples used were not microdissected and had
both tumor and stromal tissue, and therefore, the analysis may
be missing more robust predictive genes.
Given the publication of numerous studies that have
identified prognostic gene expression signatures for NSCLC,
one important question concerns the comparability of these
studies as they have used different microarray platforms,
analysis techniques, and samples. The Lu et al. study dis-
cussed above as well as other published studies72–74 have
demonstrated the feasibility of combining different datasets
to increase the power and robustness of the prognostic sig-
nature. In addition to these studies, additional work has been
done to determine the feasibility of conducting larger studies
involving the participation of multiple laboratories. Recently
a large retrospective, multisite, blinded study by Shedden et
al.75 collected 442 lung ADs with relevant clinical, patho-
logic, and outcome data at 4 institutions from 6 lung cancer
treatment sites to characterize the performance of several
prognostic models. The feasibility of the study was estab-
lished previously by comparing gene expression data pro-
duced on the same microarray platform using a standardized
protocol by the four participating institutions.76 Eight prog-
nostic classifiers and classifiers based on the work of Potti et
al.66 and Chen et al.70 were developed and evaluated on
designated training and blinded test subsets of the data and
produced variable results. The inclusion of clinical covariates
improved the performance of most classifiers, more complex
classifiers (classifiers that included more genes) had better
performance, classifiers trained across samples of all stages
performed better across Stage I samples, and a small subset of
the classifiers performed well across both tests sets (from two
different institutions).
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The study illustrates many important points concerning
the development of gene expression-based prognostic predic-
tors for early stage lung cancer. While the prognostic classi-
fiers contain different gene sets, there was some concordance
between the predictions made by each of the classifiers. This
suggests that the power of gene expression to predict prog-
nosis is not restricted to the differential expression of a few
genes and that each of the classifiers is measuring aspects of
prognosis-related lung AD biology. Similar results have been
seen in the setting of breast cancer, where various prognostic
classifiers (containing different genes) show high rates of
concordance in their outcome predictions of individual sam-
ples.77 It is interesting to note that for some lung tumor
samples there was complete agreement or disagreement be-
tween the classifiers and clinical outcome, while for other
samples there was considerable heterogeneity. There are
several possible explanations for these discrepancies. Lung
ADs have significant histologic variation and mixed sub-
types, and therefore, it is possible that for some samples, the
tissue in the sample may not accurately represent the tumor or
the biologic process on which a particular classifier depends.
In addition, heterogeneity in tissue composition and sample
processing or inaccuracies in clinical information may con-
tribute to the variability in the predictions made by the
classifiers for a particular sample. There are also potential
problems with using overall survival as an end point to
evaluate prognostic gene expression signatures in subjects
with “high risk” tumors that are completely resected or in
subjects with “low risk” tumors that develop secondary con-
ditions shortly after diagnosis. The study addresses problems
that have plagued past studies such as small number of
samples, inconsistent and variable clinical data and sample
collection and illustrates many of the remaining challenges
associated with developing a prognostic gene expression
signature for clinical application.
In addition, the MicroArray Quality Control project led
by the Food and Drug Administration evaluated microarray
technology for its use in clinical and regulatory settings by
examining repeatability of data generated within a particular
site, across multiple sites, and between seven different mi-
croarray platforms.78 The study observed reproducibility of
gene expression measurements between different sites and
platforms. The reproducibility of gene expression measure-
ments between sites and across platforms demonstrated by
these studies is a critical milestone in the development of
gene expression biomarkers that can be routinely used in the
clinic.
Prognostic miRNA Signatures for NSCLC
Before the work of Johnson et al.79 associating let-7
miRNA and RAS expression in lung cancer, Takamizawa et
al.80 demonstrated that reduced expression of let-7 miRNA in
lung cancer was associated with shortened postoperative
survival. One-hundred forty-three lung tissue specimens, pre-
dominantly ADs, from Stage I, II, and III lung cancers were
collected from patients undergoing resection. Let-7 expres-
sion was used to dichotomize patients into two groups that
had significantly different survival (p  0.0003) when all
samples were analyzed or just ADs. Patients with lower let-7
expression has significantly worse prognosis, independent of
disease stage.
Yanihara et al.55 used microarrays to quantify miRNA
expression in lung tumors and found that 2 miRNAs, mir-155
and let-7a-2, were significantly associated with survival in
lung ADs by Kaplan-Meier survival analysis. In a multivar-
iate Cox proportional hazard analysis that included all clini-
copathological and molecular factors, increased expression of
mir-155 was significantly associated with worse prognosis.
Real time RT-PCR across an independent validation set of 32
ADs confirmed a significant relationship between mir-155
expression and survival. A subsequent study by Yu et al.81
used real-time PCR to measure the expression of 157 miRNAs
in 112 NSCLC patients to identify a 5 miRNA signature
(let-7a, mir-221, mir-137, mir-372, mir-182) capable of pre-
dicting overall and relapse-free survival. Cox proportional
hazard regression and risk-score analysis was used to identify
the five miRNA signature across a training set of samples
(n  56). The signature was used to predict the risk (high- or
low-) on a test set of samples (n  56) and an independent
cohort of NSCLC samples (n  62). There was a statistically
significant difference in overall and relapse-free survival
between low- and high-risk groups and the signature was a
reasonable predictor of survival among subsets of the samples
with the same cell type or stage. Yu et al. was also able to
show that modulating the levels of four out of the five
miRNAs altered lung cancer cell invasiveness in vitro. The
results indicate that miRNA expression profiles can be used
as prognostic markers for lung cancer. Future studies profil-
ing both gene and miRNA expression across a large cohort of
early stage ADs is needed to determine if an expression
signature composed of miRNAs, mRNAs, or both has the
greatest diagnostic and prognostic potential in lung cancer.
Pharmacogenomics
Integration of diverse sources of clinical, biologic,
expression, and sequence information is the promise of per-
sonalized medicine and may make it possible to individually
tailor treatment regimens for lung cancer. For example, bi-
omarkers may identify chemotherapeutic-specific lung cancer
subtypes with the potential to improve prognosis through use
of individualized treatments. Work in this direction is already
starting to yield promising results.
Staunton et al.82 used DNA microarrays to measure
gene expression in the NCI-60 panel (a collection of 60
human cancer cell lines83,84). By combining the untreated
gene expression profile of each cell line together with infor-
mation about each cell lines’ chemosensitivity profile, they
were able to predict drug sensitivity in an independent test set
of cell lines. A subsequent study by Potti et al.85 repeated and
built upon Staunton’s work. They showed that the drug
sensitivity predictors derived from the NCI-60 data were
capable of accurately predicting patient response to various
chemotherapeutic agents, and were further able to predict that
lung cancer patients sensitive to docetaxel were likely to be
resistant to etoposide—both front-line chemotherapy options.
The work by Potti et al. also connected patterns of chemo-
therapy sensitivity with deregulation of known oncogenic
pathways. For example, a relationship between docetaxel
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resistance and deregulation of the PI3-kinase pathway was
observed. Using a panel of 17 NSCLC cell lines a significant
association was found between docetaxel resistance and sen-
sitivity to a PI3-kinase inhibitor (LY-294002), suggesting its
use as a second-line therapy.
Following the above work, Hsu et al.86 developed
predictors of cisplatin (a first line agent) and pemetrexed (a
second line agent) sensitivity using the NCI-60 data and data
from Gyorffy et al.87 They found that docetaxel, abraxane,
and pemetrexed sensitivity was significantly inversely corre-
lated with sensitivity to cisplatin (p  0.01) suggesting their
use in ciplatin-resistant patients. Another study by Gemma et
al.88 coupled gene expression data generated using 10 human
lung cancer cell lines and drug sensitivity data across 8
anticancer drugs used in lung cancer chemotherapy (do-
cetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU, SN38,
CDDP, and CBDCA) to demonstrate sensitivity to gemcitab-
ine was uncorrelated with sensitivity to the other agents,
suggesting that combination therapy regimens that include
gemcitabine might be interesting to pursue clinically.
Many of the studies described earlier in this review
profiled gene expression in primary human tumors to identify
gene expression predictors of clinical and pathologic vari-
ables. An exciting aspect of the studies described above is
that they use gene expression information from cell lines and
demonstrate that this information can lead to clinically rele-
vant predictors of drug sensitivity in lung cancer patients.
These results, while tantalizing, are preliminary and need to
be validated in larger longitudinal cohorts of lung cancer
patients being treated with various chemotherapeutic regi-
mens and followed for measures of disease outcome.
Conclusions and Future Directions
The studies described in this review demonstrate the
potential for gene expression signatures to impact lung cancer
management; however, numerous obstacles remain to the
routine application of these profiles in the clinic. Further
work on computational approaches for merging datasets
across platforms is needed to effectively leverage the collec-
tive data being generated. In addition, large longitudinal
studies measuring gene expression as well as routine clinical,
biochemical, and pathologic measures are needed to demon-
strate that gene expression is a better predictor of outcome
than more routine measures. This could be accomplished by
leveraging existing large-scale prospective clinical trials or
epidemiologic studies and collecting biologic samples for
gene expression studies from those subjects. Additionally,
integrating high-throughput gene expression measurements
with other forms of molecular data (SNPs, methylation,
proteomics) may give a more complete picture and result in
the identification of the most robust diagnostic, prognostic,
and predictive markers. However, the ultimate barrier to
adoption of these markers in the clinic is the need for more of
them to be validated in prospective multicenter studies to
demonstrate their reproducibility and accuracy across multi-
ple sites and operators. Physicians and other health care
providers will need to be trained in the proper handling and
storage of biologic specimens for gene expression studies
given RNA’s inherent instability. While the Food and Drug
Administration has begun to address some of the regulatory
issues surrounding multivariate gene expression assays, ad-
ditional guidance is needed from physicians, third-party pay-
ers, and regulatory bodies if these tests are to be translated
into clinical benefit for lung cancer patients.
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